Evaluation of aflibercept treatment responses in eyes with bevacizumab/ranibizumab-resistant wet age-related macular degeneration

8Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Objectives: To evaluate anatomic and functional results after switching from intravitreal bevacizumab or ranibizumab treatment to aflibercept for wet (neovascular) age-related macular degeneration. Materials and Methods: This retrospective study included 22 eyes of 22 patients resistant to treatment with at least 6 injections of bevacizumab or ranibizumab. The first three injections had been applied monthly, the others pro re nata (PRN). Outcome measures were follow-up period, injection number, best corrected visual acuity (BCVA), central retinal thickness (CRT) and pigment epithelial detachment (PED) height. Dosing regimen of aflibercept was determined PRN. The patients were examined monthly. In all visits, BCVA and optical coherence tomography results were assessed together and injections were applied according to these findings. Patients with at least three months of follow-up were included in the study. Results: Twenty-two eyes of 22 patients treated with bevacizumab or ranibizumab were switched to aflibercept therapy. Seven patients had serous PED and 4 patients had fibrovascular PED. The mean follow-up periods for these groups were 20.59±6.76 months and 8.68±3.79 months, respectively. The mean injection numbers were 10.5±3.61 vs 4.54±1.56. Statistically significant reductions were noted in CRT (533.86±164.06 µm vs 412.04±143.86 µm, p<0.05). BCVA levels were almost equal before and after switching (0.18±0.17 vs 0.18±0.14). Serous and fibrovascular PED heights decreased suboptimally from 460±281.51 µm to 282.42±175.76 µm (p>0.05) for serous PEDs and 251.25±43.85 µm to 225.75±73.09 µm (p>0.05) for fibrovascular PEDs. Conclusion: Switching to aflibercept resulted in significant improvement in CRT, but not in BCVA or PED heights.

References Powered by Scopus

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)

899Citations
N/AReaders
Get full text

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

894Citations
N/AReaders
Get full text

Macrophage depletion inhibits experimental choroidal neovascularization

448Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Anti-vegf-resistant retinal diseases: A review of the latest treatment options

87Citations
N/AReaders
Get full text

A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration

31Citations
N/AReaders
Get full text

Intravitreal Ziv-Aflibercept: A Comprehensive Review

13Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Topal, T., Kar, T., Yıldırım, Y., Sağdıç, S. K., Büyükavşar, C., Kaya, A., … Ünal, M. H. (2017). Evaluation of aflibercept treatment responses in eyes with bevacizumab/ranibizumab-resistant wet age-related macular degeneration. Turk Oftalmoloiji Dergisi, 47(3), 133–137. https://doi.org/10.4274/tjo.34735

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

56%

Researcher 2

22%

Professor / Associate Prof. 1

11%

Lecturer / Post doc 1

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

69%

Biochemistry, Genetics and Molecular Bi... 2

15%

Pharmacology, Toxicology and Pharmaceut... 1

8%

Agricultural and Biological Sciences 1

8%

Save time finding and organizing research with Mendeley

Sign up for free